How can information generated from advanced genomic profiling technology be turned into something clinically actionable? Successfully delivering personalized cancer medicine to patients requires a thorough understanding of how gene expression patterns relate to cancer therapy response as well as the ability to determine which information is most relevant to an individual’s disease. The evolving role of the physician in cancer treatment has become equally important and communicating test results in a concise manner is a largely unmet need.
The Inaugural Clinical Genomics for Cancer Diagnostics meeting will look at novel diagnostic tools and techniques, evaluate their benefit to patient outcome, and focus on steps to implementation. Hotspot testing will be compared to comprehensive genome profiling and emerging technologies will be explored. Considerations for molecular test development, result reporting, and patient stratification will be also addressed. Using genomic information in cancer management presents many operational challenges, but also offers an unprecedented opportunity to take the trial and error out of cancer treatment.
Topics Include:
- Interrogating Cancer Genes with NGS-Based Approaches
- Genotyping Technologies
- Data Interpretation
- Moving from Technology to Patient Treatment
- The Evolving Role of the Patient
Keynote Presentation:
Integrated Genomic Data Informs Cancer Treatment 
Elaine R. Mardis, Ph.D., Professor, Genetics and Molecular Microbiology; Co-Director, The Genome Institute, Washington University School of Medicine at Washington University Medical Center
Who Should Attend:
Pathologists, Oncologists, Medical Directors, Vice Presidents, CMOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in areas such as cancer genomics, bioinformatics, clinical genomics, pharmacogenomics, diagnostics, internal medicine, molecular biology, and translational research.